Tag Archives: ORLANDO

Shapiro Goldman Babboni & Walsh Attorneys Attend Florida Justice Association’s ‘Workhorse’ Seminar

Bernard Walsh

ORLANDO, Fla., April 6, 2016 (SEND2PRESS NEWSWIRE) -- Attorneys from the southwest Florida personal injury law firm Shapiro Goldman Babboni & Walsh attended the Florida Justice Association's annual "Workhorse" seminar held at the Orlando World Trade Center Marriott.

Opening with keynote speaker, two-time Olympic Gold Medalist and 2015 FIFA Women's World Cup champion Abby Wambach. The four day event featured dozens of seminars for civil and criminal trial attorneys and more than 100 speakers.

Members of Shapiro Goldman Babboni & Walsh attending the Workhorse seminar included Attorneys M. David Shapiro and Michele Stephan of the Sarasota Office, as well as attorneys Bernard F. Walsh, and Daniel Murphy from the law firm's Bradenton Office location.

The 30th Anniversary of the FJA Workhorse offered guests a wide variety of seminars for attorneys of all experience levels that focused on improving and building the skills needed to represent clients in various areas of legal practice. Prominent seminars during the 4-day event included sessions on Florida's adoption of Daubert vs Frye, representing clients who have suffered traumatic brain injury, trial preparation, proving and arguing damages and representing clients in premises liability claims.

Attorney Bernard Walsh had this comment about the event, "The FJA Workhorse seminar is one of the most important continuing legal education events held in Florida each year. 'Workhorse' is a rare opportunity to network with so many attorneys and legal professionals from around the State. Participants of the seminar help to foster a valuable exchange of ideas and experiences that contribute to strengthening the Florida legal system, and is especially valuable as attorneys must now adjust courtroom strategies around Daubert."

About Attorney Bernard F. Walsh:

A highly experienced AV rated attorney and founder of the Manasota Trial Lawyers Board, Bernard Walsh is an active member in multiple legal organizations including the Association of Plaintiff Interstate Trucking Lawyers of America (APITLA), the Multi-Million Dollar Advocates Forum, the Florida Justice Association, the National Trial Lawyers Association and the National Association of Distinguished Counsel.

Bernard Walsh is an active member of the Manatee and Sarasota Sheriff's Advisory Boards, the Florida Highway Patrol Advisory Council and the One Hundred Club for Law Enforcement in Manatee.

Partner at the Personal Injury and Civil Trial Law firm of Shapiro, Goldman, Babboni and Walsh, Bernard Walsh has helped hundreds of Floridians get fair compensation for injuries. Additionally, Bernard Walsh has won one of Florida's largest motorcycle accident recoveries and has an AV Preeminent(R) rating on Martindale-Hubbel(R), a doctors and attorneys ratings website and is a Superb rated attorney with Avvo.com.

Shapiro Goldman Babboni & Walsh
5291 Office Park Boulevard, Bradenton FL, 34203
Local: 941-752-7200

More information: http://www.GetMejustice.com/.

Twitter: @GetMeJustice

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/Shapiro-Goldman-Babboni-Walsh-Attorneys-Attend-Florida-Justice-Association-s-Workhorse-Seminar-2016-0406-04.shtml.

NEWS SOURCE Shapiro Goldman Babboni and Walsh :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11

medical devices

ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTC:MDIT, the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, Calif.

MEDITE, a USA based company now public through the merger with CytoCore Inc. has emerged as a German manufacturer focused on global sales of cancer diagnostic tools consisting of anatomic pathology, histology and cytology laboratory equipment and supplies. Recent agreements with U.S. distribution partners, Hospital Group Purchasing Organizations along with our Chinese partner UNIC Medical will allow the company to focus growth from historically based European sales to entry into the U.S., Latin America and a burgeoning and untapped Chinese market.

UNIC Medical selling MEDITE's equipment, which is already Chinese FDA registered, and cytology assays and stains is involved with the Chinese government in establishing first time country pathology standards for digitalized computer aided diagnosis of cancer in China, a country of 1.4 billion people with a lack of sufficient number of pathologists. As the company expands consumable cytology sales for cervical and breast cancer worldwide, current profitability should significantly expand as margins increase in the near future.

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations.

About MEDITE Cancer Diagnostics, Inc.:

MEDITE Cancer Diagnostics, Inc. is a Delaware registered company consisting of wholly-owned MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement:

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE's ability to maintain and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form 10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: http://www.medite-group.com/.

Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630

*LOGO for media: send2press.com/mediaboom/16-0107-medite-diag-300dpi.jpg

REF: OTCMKTS:MDIT

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medite-cancer-diagnostics-inc-will-present-at-the-seethruequity-healthcare-investor-conference-on-january-11-2016-0107-04.shtml.

NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.

MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

premium medical devices

ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the "Company" / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.

The Company reports $2.7 million of revenues and an operating profit of $132,000 for the third quarter. For the nine months ended September 30, 2015, revenues were $7.1 million with an operating loss of $58,000. Comparability between the third quarters and nine month periods ending 2015 and 2014 must consider the dollar's 18 percent appreciation during the latter part of 2014 and 2015, along with the exclusion of $358,000 premerger expenses in the 2014 first quarter related to CytoCore, Inc. Approximately 85 percent of the Company's revenues invoiced in Euro currency are generated by the European subsidiaries and were up approximately 5 percent for the nine month period.

Introduction of innovative new products and significant growth in new markets, such as China and Latin America, have resulted in a record for year-end orders. Third quarter orders were up 75 percent compared to last year.

"We expect the upside trend to continue in 2016 as MEDITE benefits from new worldwide histology and cytology product introductions, recent Chinese FDA approvals for histology products and expected Chinese FDA approval for cytology products," stated CEO Michaela Ott.

About MEDITE Cancer Diagnostics, Inc.:

MEDITE Cancer Diagnostics, Inc. is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement:

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE's ability to maintain and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form 10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: http://www.medite-group.com/.

Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630

REF: OTCMKTS:MDIT / OTC:MDIT

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medite-cancer-diagnostics-inc-reports-a-profitable-third-quarter-and-nine-month-2015-results-2015-1117-05.shtml.

NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.

ScoopCloud Newswire

Transportation Futurist Simon Anderson to Speak at TransForum 2015

ORLANDO, Fla., Sept. 8, 2015 (SEND2PRESS NEWSWIRE) -- International futurist and award-winning author Simon Anderson, founder of Venture Foresight, LLC, has been selected to be a featured speaker at the TMW TransForum user conference on Sept. 14, 2015 in Orlando. Anderson will focus on the near-future of trucking and transportation in his presentation.

Thought-provoking keynote speaker, transportation futurist, and author, Simon Anderson has been selected to join speakers including Jeffrey Baxter at the annual TMW TransForum User Conference. On September 14, 2015, Anderson will be speaking at a featured session where he'll be discussing new technologies and trends that are transforming transportation and trucking and how businesses and other organizations can better position themselves for an uncertain future.

The presentation, drawn partially from the new edition Anderson's award-winning book "Foresight 20/20: A Futurist Explores the Trends Transforming Tomorrow [Updated & Expanded]" (co-authored with globally acclaimed futurist Jack Uldrich) will discuss trends and technologies including automation, advancements in AI, robotics, and wearables. He will also speak about generational trends, the future of work, unlearning, and creating a corporate culture that can adapt and thrive in a fast-changing world.

"The world is being transformed by exponential advancements in technology and every one of our lives and careers will be touched by these advancements," says Anderson. "My role as a futurist is to be a catalyst for discussion, and to help leaders recognize opportunities before they become challenges."

In the past year, Anderson has addressed businesses and other organizations around the country and in Canada including Wake Tech in Raleigh, N.C., the Agricultural Service Boards of Alberta, in Edmonton, and the North Dakota Department of Transportation, in Bismarck. His work has also been featured in a variety of publications including the World Future Society's site - http://www.wfs.org/ - and the Austrian management magazine, the Hernsteiner.

Parties interested in learning more about Simon Anderson, his book "Foresight 20/20" (ISBN: 978-1592988945), his blog or his speaking availability are encouraged to visit his website at: http://www.ventureforesight.com/.

Twitter: @Futur1st

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/transportation-futurist-simon-anderson-to-speak-at-transforum-2015-0908-05.shtml.

NEWS SOURCE Venture Foresight LLC :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.